PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Treated with First Line Chemoimmunotherapy
Version 1
: Received: 23 May 2024 / Approved: 23 May 2024 / Online: 23 May 2024 (09:44:28 CEST)
How to cite:
Putzu, C.; Serra, R.; Campus, R.; Fadda, G. M.; Sini, C.; Marongiu, A.; Ginesu, G. C.; Fois, A. G.; Palmieri, G.; Zinellu, A.; Cossu, A.; Paliogiannis, P. Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Treated with First Line Chemoimmunotherapy. Preprints2024, 2024051526. https://doi.org/10.20944/preprints202405.1526.v1
Putzu, C.; Serra, R.; Campus, R.; Fadda, G. M.; Sini, C.; Marongiu, A.; Ginesu, G. C.; Fois, A. G.; Palmieri, G.; Zinellu, A.; Cossu, A.; Paliogiannis, P. Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Treated with First Line Chemoimmunotherapy. Preprints 2024, 2024051526. https://doi.org/10.20944/preprints202405.1526.v1
Putzu, C.; Serra, R.; Campus, R.; Fadda, G. M.; Sini, C.; Marongiu, A.; Ginesu, G. C.; Fois, A. G.; Palmieri, G.; Zinellu, A.; Cossu, A.; Paliogiannis, P. Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Treated with First Line Chemoimmunotherapy. Preprints2024, 2024051526. https://doi.org/10.20944/preprints202405.1526.v1
APA Style
Putzu, C., Serra, R., Campus, R., Fadda, G. M., Sini, C., Marongiu, A., Ginesu, G. C., Fois, A. G., Palmieri, G., Zinellu, A., Cossu, A., & Paliogiannis, P. (2024). Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Treated with First Line Chemoimmunotherapy. Preprints. https://doi.org/10.20944/preprints202405.1526.v1
Chicago/Turabian Style
Putzu, C., Antonio Cossu and Panagiotis Paliogiannis. 2024 "Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Treated with First Line Chemoimmunotherapy" Preprints. https://doi.org/10.20944/preprints202405.1526.v1
Abstract
Background: The aim of this study was to investigate a series of complete blood cell count – based biomarkers of systemic inflammation as predictors of clinical outcomes in patients who underwent first-line chemoimmunotherapy for advanced NSCLC. Methods: Consecutive patients with pathologically diagnosed stage III/IV NSCLC who underwent first-line chemoimmunotherapy were retrospectively enrolled. The clinical outcomes used for biomarker evaluation were Objective Response Rate (ORR) and Overall Survival (OS). Results: Non-responders had significantly higher values of neutrophil to lymphocyte ratio (NLR, median: 5.36; IQR: 2.78–10.82 vs. 3.31; IQR: 2.15–4.12, p = 0.019), neutrophil to monocyte ratio (NMR, median: 14.00; IQR: 8.82–21.20 vs. 9.20; IQR: 7.45–11.20, p = 0.013), and systemic inflammation index (SII, median: 1,395; IQR: 929–3,334 vs. 945; IQR: 552–1,373, p = 0.025), but only NLR and NMR remained independently related with clinical response in multivariate logistic regression. In univariate analysis white blood cells (OR:1.2202; 95% CI: 1.0339 - 1.4400, p=0.019), neutrophils (OR:1.2916; 95% CI: 1.0692 - 1.5604, p=0.008), NLR (OR:1.3601: 95% CI: 1.0949 - 1.6896, p=0.005) and NMR (OR:1.2159; 95% CI: 1.00396 - 1.4221, p=0.015) were significantly associated with survival; Cox regression models confirmed that neutrophils, NLR and MLR were independently associated with survival; NLR at a cut-off value of 4.0 showed the better AUC (0.749) in predicting survival. Conclusions: Baseline complete blood cell count biomarkers, especially the NLR, can predict clinical outcomes in patients with advanced NSCLC treated with first-line chemoimmunotherapy.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
